Preventing Cognitive Decline by Reducing BP Target Trial (PCOT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05106036|
Recruitment Status : Recruiting
First Posted : November 3, 2021
Last Update Posted : September 1, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Cognitive Decline Blood Pressure Hypertension||Other: Clinical Support Decision Tool||Not Applicable|
Aim 1 The main aim is to compare the effects of intensive BP intervention between the intervention and usual care arm on the rate of change in TICS-m per year. The investigators will recruit 4,000 patients over 70 years of age with BP >130/80 mmHg from 2 diverse health systems and randomize patients within each health system to usual care or to a combination of care with clinical decision support, practice facilitators and Pharm Ds to lower home BP to < 130/80 mmHg. The primary outcome of this trial will be development cognitive decline as determined by a decrease in TICS-m scores from baseline. As a secondary outcome, the investigators will also measure the development of mild cognitive impairment or dementia in a subset of patients who show a decline of ≥3 points through adjudication.
Aim 2a Determine the potential harms of intensive lowering BP. The investigators aim to recruit 4,000 study participants and compare the effects of lowering home BP below 130/80 mmHg with usual care on hospitalizations, emergency department visits, cardiovascular events, deaths, syncope, falls, fractures, hypotension, electrolyte abnormalities and acute kidney injury. The investigators will capture measures of adherence and health care resource utilization. The investigators will assess QOL in 4,000 patients. The investigators will capture possible harms of lowering BP below 130/80 mmHg. The investigators have chosen clinical outcomes of relevance to all the stakeholders based on prior experience on pragmatic clinical trials and our prior experience in ICD-Pieces. Outcomes will be captured from the telephone assessment by study personnel and electronic health records and/or claims data and reflecting possible harms from all participants will include hospitalizations, emergency department visits, cardiovascular events, deaths, syncope, hypotension, falls, fractures, electrolyte disturbances and acute kidney injury. There will also be capture of adherence by pharmacy refill data. The investigators will capture BP readings from each visit. The investigators will also capture number of encounters with the health system as a measure of health care utilization.
Aim 2b Determine the impact of intensive BP management on QOL. Determine the impact of intensive BP management on QOL. Quality of life (QOL) scores will be obtained using the PROMIS Scale v1.2 - Global Health instrument annually after the administration of the TICS-m.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||4000 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Investigator, Outcomes Assessor)|
|Official Title:||Preventing Cognitive Decline by Reducing BP Target Trial|
|Actual Study Start Date :||July 11, 2022|
|Estimated Primary Completion Date :||August 31, 2025|
|Estimated Study Completion Date :||August 31, 2025|
Experimental: Intervention Arm
Home BP data will be averaged each month via OmronConnect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health.Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the CDS (Clinical Decision Support) tool to assist their physicians with their blood pressure management. Study Team will not be involved in treatment decision making, it will be determined by subject's treating physician. .
Other: Clinical Support Decision Tool
Participants whose home blood pressure reading average is systolic ≥ 130 and diastolic ≥ 80 will trigger the Clinical Decision Support (CDS) tool to assist their physicians with their blood pressure management. Home BP data will be averaged each month via Omron Connect app on the patients' smartphone, which is programmed to send home BP readings to MyChart via Apple or Google Health. We have designed CDS to present treatment choices of antihypertensive medication regimen based on medications patients are currently taking. For example, patients who are currently taking an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), our CDS algorithm will recommend addition of a calcium channel blocker as the first tier of recommendation and thiazide diuretics as second tier of recommendation. Laboratory data and home BP in the past month will be presented in a clear and simple manner for the clinicians to activate and use to optimize BP control.
No Intervention: Usual Care Arm
Physicians will continue to make decisions about the participant's blood hypertension management as usual without the CDS tool.
- Cognitive Decline [ Time Frame: 4 years ]Rate of change in Modified Telephone Interview for Cognitive Status (TICS-m) test between study arms. The test has scores ranging from 0 to 42 with higher values indicating better cognitive status.
- Mild Cognitive Decline or Dementia [ Time Frame: 4 years ]Development of mild cognitive decline or dementia as determined through adjudication from cognitive experts between study arms
- Number of Pharmacy Refills [ Time Frame: 4 years ]Between the two groups
- Change in quality of life assessment [ Time Frame: 4 years ]Quality of life (QOL) scores will be obtained using the PROMIS Scale v1.2 - Global Health instrument annually. The investigators will assess change in quality of life across the four years between the two groups. The Global Health instrument has scores ranging from 4 to 20 for their Mental and Physical Health Items with higher values indiciating better global health.
- Number of encounters within the participant's health system [ Time Frame: 4 years ]The number of encounters within the participant's respective health system between the two groups will be used to assess healthcare utilization.
- Systolic and Diastolic BP Readings [ Time Frame: 4 years ]Between the two groups
- Combination Pill Use [ Time Frame: 4 years ]Between the two groups
- BP Above 130/80 [ Time Frame: 4 years ]Between the two groups
- Count of individuals who experience any of the following safety events: hospitalizations and emergency room visits [ Time Frame: 4 years ]Total number of hospitalizations and emergency room visits related to cardiovascular events, syncope, hypotension, falls, fractures, electrolyte disturbances and acute kidney injury between the two groups.
- Number of reported deaths [ Time Frame: 4 years ]Count of the number of reported deaths between the two groups
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||70 Years and older (Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- High BP defined as at least 2 BP readings of SBP >= 130 or DBP >=80 during the 24 months prior to enrollment
- Clinic visit with primary care provider within the last 24 months
- Ability to write and speak English or Spanish
- 70 years of age or older 5 - Ability to understand and willingness to provide informed consent
- Owns a smartphone or tablet
- Blood pressure consistently <130/80 mmHg
- Presence of dementia, Alzheimer's disease, or significant neurological disease
- Major and unstable heart disease (e.g., acute heart failure (systolic or diastolic), acute on chronic heart failure (systolic or diastolic), acute coronary syndrome or cardiac arrest, liver or renal transplantation
- Under 70 years of age
- Inability to write or speak English or Spanish
- Chronic kidney disease stage 5 or ESKD
- Any conditions judged by the medical providers to contraindicate participation due to risk to patient safety or lack of adherence
- Expected life expectancy under a year
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05106036
|Contact: Venkatraghavan Sundaram, Ph.D.||email@example.com|
|Contact: Miguel Vazquez, MDfirstname.lastname@example.org|
|United States, Texas|
|UT Southwestern Medical Center||Recruiting|
|Dallas, Texas, United States, 75390|
|Contact: Miguel Vazquez, MD 214-648-3442 Miguel.Vazquez@UTSouthwestern.edu|
|Contact: Wanpen Vongpatanasin, MD 214-648-9078 Wanpen.Vongpatanasin@UTSouthwestern.edu|
|Responsible Party:||Miguel Vazquez, Professor, Clinical Director, Division of Nephrology, University of Texas Southwestern Medical Center|
|Other Study ID Numbers:||
R33AG068486 ( U.S. NIH Grant/Contract )
|First Posted:||November 3, 2021 Key Record Dates|
|Last Update Posted:||September 1, 2022|
|Last Verified:||August 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|